Conditions and areas
Area by area: where research and clinical practice in Japan stand for joints, diabetes, Parkinson’s disease, premature ovarian insufficiency, osteonecrosis of the femoral head and hair loss, and what to ask before you go. Information only; suitability is for a doctor to decide.
01What this topic covers
- Joints and sports injuries
- Diabetes
- Parkinson’s disease
- Premature ovarian insufficiency
- Osteonecrosis of the femoral head
- Hair loss
02Which class it generally falls into in Japan
- iPS cells, ES cells and similar: generally Class I (high risk).
- The patient’s own somatic stem cells (e.g. adipose-derived stem cells): generally Class II (medium risk).
- Somatic cell processing without stem cells (e.g. immune cell therapy): generally Class III (low risk).
- PRP depends on how it is used: injection into a joint or other “non-homologous use” is Class II (medium risk); dental and similar uses are mostly Class III.
This is how treatments generally map; the class of a specific treatment is whatever the clinic’s submitted plan states.
Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); MHLW division notice, risk-classification chart; checked 2026-11
03Guides in this topic
Guides are on the way
Guides for this topic are being prepared, each with its sources and the date it was checked. Meanwhile, start with these pages.